Keywords: five, key, products, continue, drive, merck, co
Five key products continue to drive Merck & Co sales in 2001
Article | 28 January 2002
Merck & Co has posted an 18% increase in sales to $47.7 billion forfull-year 2001, while net income rose 7% to $7.28 billion or $3.14 per share (+8%). ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
